Search results for

As the Gulf Cooperation Council’s patent system goes from strength to strength, Ralph Cunningham examines how patent owners are benefiting from improved protection and enforcement throughout the region

Artistic copyright has sometimes been seen as the Cinderella of copyright law. Simon Stokes argues that recent artistic copyright cases in Europe and North America are pushing copyright law to its limits. This has implications for the creative industries generally.

Jane Mutimear examines how the courts in Germany and the UK, as well as OHIM, have treated trade mark applications arising from generic domain names

"We are also seeing companies getting back to basics and building their core brands that consumers already know"

? China: The State Council unveiled a new statute on copyright protection of computer software on January 11. The new legislation, which runs to 33 articles, states that an individual software developer shall retain his copyright throughout his life and for 50 years after his death.

Administrators of commercial companies in Colombia, whether national or foreign, must submit a report of performance to a general shareholders meeting. This must be done within the first three months of the fiscal year. Contained in the report must be a disclosure of the company's compliance with the provisions on IP and copyright.

Ralph Cunningham, Hong Kong

Interview: Anne Chasser Ingrid Hering interviews Anne Chasser, Commissioner for Trademarks at the US Patent and Trademark Office. Formerly the director of Trademarks and Licensing Services at Ohio State University, she has also served as president of the International Trademark Association and is a founder of the Association of Collegiate Licensing Administrators.

Fifth International Publishers Association Copyright Conference, February 20-22 2002, Accra, Ghana. Details at www.ipa-uie.org, or the Ghana Book Publishers Association, email: ipa2002@ghana.com

Pharmacia Corp, GD Searle & Co and Pfizer Inc (the patentees) were the proprietors of European Patent (UK) 0 679 157 (the patent) relating to chemical compounds having use as non-steroidal anti-inflammatory drugs (NSAIDs). The patentees appealed the findings at trial that the patent was invalid and not infringed by the defendants, Merck & Co Inc and Merck Sharp & Dohme Ltd (Merck). On appeal, the finding of invalidity was confirmed (Court of Appeal, December 14 2001). Merck's chemical compound, sold under the name Vioxx, was held to fall within claim 1 and would have infringed if the claim had not been held invalid.